EUVIMEDEUVIMED entdecken
Crossref

Noninvasive Imaging of Claudin 18.2 Expression in Gastric Adenocarcinoma: Synthesis, Preclinical Evaluation, and Preliminary Clinical Study of a Novel [89Zr]Zr-DFO-NY005 Immuno-Positron Emission Tomography Tracer

Jialiang Wang, Kequan Lou, Liping Chen, Yu Zhang, Huihui He, Qiaoling Xu, Najing Wu, Quanpeng Wang, Qingbo Li, Yanjuan Wang, Haitian Fu, Chunjing Yu und 1 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2025.09.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Jialiang Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Zirconium, Claudins, Radioisotopes. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Jiangnan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Claudin 18.2 (CLDN18.2) is predominantly expressed in the gastric mucosa and becomes exposed and accessible during malignant transformation. Its highly restricted expression pattern and function in gastric cancer (GC) make CLDN18.2 a promising target for the treatment of GC. Accordingly, the accurate assessment of CLDN18.2 expression is imperative for CLDN18.2-targeted cancer therapeutics. In this study, we aimed to develop a CLDN18.2-targeting positron emission tomography (PET) probe for the in vivo assessment of CLDN18.2 expression. METHODS AND MATERIALS: Anti-CLDN18.2 recombinant single-chain antibody fused with IgG1-fragment crystallizable (VHH-Fc) fusion protein NY005 was radiolabeled using p-isothiocyanatobenzyl-desferrioxamine B chelator and 89Zr to obtain the [89Zr]Zr-DFO-NY005 PET probe. The specific activity, radiochemical purity, and the stability of the probe were then assayed. We evaluated the CLDN18.2-targeting capability of [89Zr]Zr-DFO-NY005 in the A549hCLDN18.2 xenograft tumor model and investigated its biodistribution, pharmacokinetics, and biosafety in Institute of Cancer Research mice. Furthermore, we performed the PET/computed tomography imaging of [89Zr]Zr-DFO-NY005 in patients with GC to assess the clinical application potential. RESULTS: The successfully synthesized [89Zr]Zr-DFO-NY005 exhibited promising specific activity, radiochemical purity, and stability and demonstrated excellent targeting capability against CLDN18.2 in the A549hCLDN18.2 xenograft tumor model. After administration, [89Zr]Zr-DFO-NY005 was mainly distributed in the liver, spleen, and kidneys of Institute of Cancer Research mice. In vivo assessment showed that [89Zr]Zr-DFO-NY005 had a T1/2α of 2.6 hour and a T1/2β of 98.84 hour, with no apparent toxicity detected. PET/computed tomography imaging performed in patients with GC demonstrated the capability of [89Zr]Zr-DFO-NY005 for the noninvasive assessment of CLDN18.2 expression. CONCLUSIONS: We successfully developed a CLDN18.2-targeting PET probe, [89Zr]Zr-DFO-NY005, and demonstrated promising capability for the evaluation of CLDN18.2 expression in GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsZirconiumClaudinsRadioisotopesAdenocarcinomaPositron-Emission TomographyDeferoxamineRadiopharmaceuticalsAnimalsHumansMiceFemaleTissue DistributionCell Line, TumorMice, NudeMalePositron Emission Tomography Computed Tomography

Substanzen

ZirconiumClaudinsRadioisotopesZirconium-89CLDN18 protein, humanDeferoxamineRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China.
  • Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. Electronic address: phie136@sina.com.
  • Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China. Electronic address: ycjwxd1978@jiangnan.edu.cn.
  • Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China. Electronic address: mydoctorwx@aliyun.com.

Förderung

  • Jiangnan University

Zitieren

APA

Wang, J., Lou, K., Chen, L., Zhang, Y., He, H., Xu, Q., Wu, N., Wang, Q., Li, Q., Wang, Y., Fu, H., Yu, C., & Mao, Y. (2026). Noninvasive Imaging of Claudin 18.2 Expression in Gastric Adenocarcinoma: Synthesis, Preclinical Evaluation, and Preliminary Clinical Study of a Novel [89Zr]Zr-DFO-NY005 Immuno-Positron Emission Tomography Tracer. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.09.022

Vancouver

Wang J, Lou K, Chen L, Zhang Y, He H, Xu Q, et al. Noninvasive Imaging of Claudin 18.2 Expression in Gastric Adenocarcinoma: Synthesis, Preclinical Evaluation, and Preliminary Clinical Study of a Novel [89Zr]Zr-DFO-NY005 Immuno-Positron Emission Tomography Tracer. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.09.022

BibTeX
@article{Wang2026,
  author = {Wang, Jialiang and Lou, Kequan and Chen, Liping and Zhang, Yu and He, Huihui and Xu, Qiaoling and Wu, Najing and Wang, Quanpeng and Li, Qingbo and Wang, Yanjuan and Fu, Haitian and Yu, Chunjing and Mao, Yong},
  title = {Noninvasive Imaging of Claudin 18.2 Expression in Gastric Adenocarcinoma: Synthesis, Preclinical Evaluation, and Preliminary Clinical Study of a Novel [89Zr]Zr-DFO-NY005 Immuno-Positron Emission Tomography Tracer},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2025.09.022}
}
Kostenlos starten →